Pfizer beats by $0.02, misses on revs; reaffirms FY17 EPS guidance, revs guidance
- Reports Q1 (Mar) earnings of $0.69 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of $0.67; revenues fell 1.7% year/year to $12.78 bln vs the $13.09 bln Capital IQ Consensus.
- Co reaffirms guidance for FY17, sees EPS of $2.50-2.60 vs. $2.55 Capital IQ Consensus Estimate; sees FY17 revs of $52-54 bln vs. $53.15 bln Capital IQ Consensus Estimate.
- "Today we are reaffirming our 2017 financial guidance, reflecting our performance to date as well as our confidence in the business going forward. Excluding the negative impacts of the divestiture of HIS and foreign exchange, the midpoints of our 2017 revenue and Adjusted diluted EPS guidance ranges reflect 4% and 10% operational growth, respectively."